Medacta Group SA, a family-owned Swiss company developing orthopedic implants, is planning an IPO on the SIX Swiss Exchange, Reuters reported.
The planned IPO would be a secondary offering and is expected to close in the second quarter of 2019. The Siccardi family, which founded the company, is expected to retain control after the offer.
An over-allotment option is also planned on existing shares, Reuters said.
Credit Suisse and Morgan Stanley are acting as joint global coordinators for the IPO, while JP Morgan and UBS Investment Bank are the joint bookrunners for the offer. Rothschild was also appointed as independent financial adviser to the Swiss company.